Olivier Martinez

Operates as clinical-stage biopharmaceutical company, focuses on the development of novel treatments for serious chronic diseases

BG is a venture capital investment management firm specialized in early-stage financing of biotechnology companies. They target start-ups with high growth potential, spawned by French and European public or private sector life science research, and more particularly applications in the healthcare, environment, agricultural and food industries. Within the healthcare sector BG focuses on biopharmaceuticals, medical instrumentation and diagnosis systems. BG provides seed capital, generally investing in the first institutional round of financing, and later participating in subsequent rounds. The firm usually joins forces with French or foreign co-investors. BG invests in France and in Europe. The firm sources deals through their extensive network in the French academic community and in the biopharmaceutical industry. BG is an active investor who sits on the board and provides strategic advisory as well as development assistance to their portfolio companies.

Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes

Develops and manufactures drugs for immune modulation

Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases

Functions as a College/University

Functions as a College/University

BPIfrance Investissement is an active manager focused on small, medium and intermdiate-sized businesses with high-growth potential. They favor sectors related to industry and technology and focus on investments in France. The firm invests either directly through dedicated investment funds or indirectly through private equity funds, partnerships and fund of funds managed by third parties. They invest across development stages, from start-ups to small LBO operations resulting from corporate succession issues. Their deal-sourcing process is both regional and national.

CDC Croissance develops an investment strategy for their clients based on each client's financial goals, time horizon and risk tolerance.